FIG. 6.

Effect of FK228 pretreatment on CAV-2 vector transduction efficiency in lungs. (A) BEAS2B and A549 human pulmonary cells were treated with FK228 (0 to 5 ng/ml) for 24 h before infection with CAVGFP (50 or 100 infectious particles/cell, respectively). Cells were analyzed by flow cytometry 24 h postinfection. (B) C57BL/6 mice were treated with FK228 (0 to 50 μg/kg) by i.n. instillation 24 h before i.n. inoculation with CAVβgal (5 × 10¹⁰ p.p.). Lungs were then recovered after intracardiac perfusion with PBS, and β-Gal activity was measured using a luminescent assay and normalized with the concentration of proteins in each homogenate. β-Gal activity in lungs from PBS- and FK228-treated mice was not significantly different (not shown). Each bar represents the mean ± standard error of the mean (n = 4/group). RLU, relative light units; *, P < 0.05.